Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

New Diabetes Drug Fights Obesity While Controlling Glucose Metabolism

By BiotechDaily International staff writers
Posted on 11 Nov 2013
Print article
A synthetic peptide that targets receptors for the naturally occurring incretin hormones GLP-1 and GIP is being developed into a drug for the management of diseases associated with impaired glucose tolerance.

Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. They also inhibit glucagon release from the alpha cells of the Islets of Langerhans.

The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

Investigators at Indiana University (Bloomington, USA) developed a "unimolecular dual incretin" derived from an intermixed peptide sequence from GLP-1 and GIP. They reported in the October 30, 2013, online edition of the journal Science Translational Medicine that this compound corrected two causal mechanisms of diabetes-linked obesity, i.e., adiposity-induced insulin resistance and pancreatic insulin deficiency, more effectively than did selective mono-agonists. This superior efficacy translated across rodent models of obesity and diabetes, including db/db mice and ZDF rats, to primates (cynomolgus monkeys and humans).

"The current study demonstrates clearly that combining GLP-1 and GIP can produce improved therapeutic effects," said contributing author Dr. Richard DiMarchi, professor of chemistry at Indiana University. "It achieved results comparable to those that resulted from a 10-fold higher dose of agents that target only GLP-1 receptors."

"The results demonstrate that GLP-1 and GIP, when built into a single molecule, provide synergistic activity to control glucose and lower body weight across a spectrum of animal models, including in human clinical experiments," said Dr. DiMarchi. "Currently approved drugs are quite effective, but they are insufficient in normalizing glucose, and they certainly do not cause much loss of body weight."

Clinical trials conducted by Roche (Basel, Switzerland) demonstrated a decrease in glucose levels beyond what would be expected from conventional treatment. However, the six-week trial was not of significant duration to provide definitive evidence about weight loss in humans.

Related Links:

Indiana University
Roche 



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.